$9.23
5.24% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Capricor Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Capricor Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Capricor Therapeutics, Inc. Price Target

Target Price $43.71
Price $9.74
Potential
Number of Estimates 7
7 Analysts have issued a price target Capricor Therapeutics, Inc. 2026 . The average Capricor Therapeutics, Inc. target price is $43.71. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 7 Analysts recommend Capricor Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Capricor Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Capricor Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 22.27 71.26
11.56% 219.97%
EBITDA Margin -184.73% 8.84%
102.15% 104.79%
Net Margin -235.37% -19.45%
56.66% 91.74%

6 Analysts have issued a sales forecast Capricor Therapeutics, Inc. 2025 . The average Capricor Therapeutics, Inc. sales estimate is

$71.3m
Unlock
. This is
219.97% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$181m 713.20%
Unlock
, the lowest is
$12.0m 46.12%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $22.3m 11.56%
2025
$71.3m 219.97%
Unlock
2026
$112m 56.99%
Unlock
2027
$205m 82.91%
Unlock
2028
$294m 43.89%
Unlock
2029
$449m 52.36%
Unlock

1 Analyst has issued an EBITDA forecast Capricor Therapeutics, Inc. 2025 . The average Capricor Therapeutics, Inc. EBITDA estimate is

$6.3m
Unlock
. This is
115.31% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$6.3m 115.31%
Unlock
, the lowest is
$6.3m 115.31%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-41.1m 78.79%
2025
$6.3m 115.31%
Unlock
2026
$-32.2m 611.11%
Unlock

EBITDA Margin

2024 -184.73% 102.15%
2025
8.84% 104.79%
Unlock
2026
-28.78% 425.57%
Unlock

5 Capricor Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Capricor Therapeutics, Inc. net profit estimate is

$-13.9m
Unlock
. This is
74.66% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$74.3m 235.84%
Unlock
, the lowest is
$-66.1m 20.83%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-52.4m 38.55%
2025
$-13.9m 73.56%
Unlock
2026
$19.1m 237.45%
Unlock
2027
$57.2m 200.26%
Unlock
2028
$153m 166.68%
Unlock
2029
$258m 69.33%
Unlock

Net Margin

2024 -235.37% 56.66%
2025
-19.45% 91.74%
Unlock
2026
17.03% 187.56%
Unlock
2027
27.96% 64.18%
Unlock
2028
51.81% 85.30%
Unlock
2029
57.58% 11.14%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.15 -0.30
38.55% 73.91%
P/E negative
EV/Sales 4.18

5 Analysts have issued a Capricor Therapeutics, Inc. forecast for earnings per share. The average Capricor Therapeutics, Inc. EPS is

$-0.30
Unlock
. This is
75.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.63 235.83%
Unlock
, the lowest is
$-1.45 20.83%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.15 38.55%
2025
$-0.30 73.91%
Unlock
2026
$0.42 240.00%
Unlock
2027
$1.26 200.00%
Unlock
2028
$3.35 165.87%
Unlock
2029
$5.67 69.25%
Unlock

P/E ratio

Current -8.14 4.36%
2025
-32.04 293.61%
Unlock
2026
23.30 172.72%
Unlock
2027
7.76 66.70%
Unlock
2028
2.91 62.50%
Unlock
2029
1.72 40.89%
Unlock

Based on analysts' sales estimates for 2025, the Capricor Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 13.39 88.06%
2025
4.18 68.75%
Unlock
2026
2.67 36.30%
Unlock
2027
1.46 45.33%
Unlock
2028
1.01 30.50%
Unlock
2029
0.66 34.37%
Unlock

P/S ratio

Current 19.98 135.94%
2025
6.24 68.75%
Unlock
2026
3.98 36.30%
Unlock
2027
2.17 45.33%
Unlock
2028
1.51 30.50%
Unlock
2029
0.99 34.37%
Unlock

Current Capricor Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Cantor Fitzgerald
Locked
Locked
Locked Mar 20 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 20 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 02 2025
Jones Trading
Locked
Locked
Locked Nov 18 2024
Cantor Fitzgerald
Locked
Locked
Locked Nov 14 2024
Analyst Rating Date
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 20 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 20 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 02 2025
Locked
Jones Trading:
Locked
Locked
Nov 18 2024
Locked
Cantor Fitzgerald:
Locked
Locked
Nov 14 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today